3 results
Primary objective:• To evaluate biodistribution of 89Zr-atezolizumab in patients with high risk DLBCL at diagnosis.Secondary objective:• To assess the heterogeneity of 89Zr-atezolizumab tumor uptake in high-risk DLBCL before R-CHOP.• To correlate…
The primary objective of this study is to generate reference values for NFMS parameters as well as for 2D-STE parameters during the second trimester, 16 until 28 weeks gestational age. The secondary objective is to investigate the diagnostic…
To investigate how safe the new medicine pralsetinib is when it is administered to patients with non-resectable advanced solid tumor cancers including non-small cell lung cancer (NSCLC) and Thyroid cancers.